There are other limitations in this study: Tregs inTMAs were only identified by Foxp3 markers, but not simultaneously analysed by CD4 and CD25; in preclinical tumor models, one experiment with 5 mice per group was not robust enough, more mice should be included, paticularly a validation in expanded mouse tumor models is necessary. The gene discussed is CD4; the disease is neoplasm.